Race-based therapeutics.
Bloche
M Gregg
MG
Georgetown University Law Center, Washington, DC, USA.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D044383:Black People / Q000235:genetics*; D017277:Drug Approval; D004338:Drug Combinations; D004345:Drug Industry; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000208:ethnology*; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use*; D007548:Isosorbide Dinitrate / Q000627:therapeutic use*; D020030:Nitric Oxide Donors / Q000627:therapeutic use*; D010330:Patents as Topic; D010597:Pharmacogenetics; D014481:United States; D014486:United States Food and Drug Administration; D014665:Vasodilator Agents / Q000627:therapeutic use; D001741:Black or African American
D000806:Angiotensin-Converting Enzyme Inhibitors; D004338:Drug Combinations; D020030:Nitric Oxide Donors; D014665:Vasodilator Agents; D006830:Hydralazine; D004656:Enalapril; D007548:Isosorbide Dinitrate